EnGeneIC Ltd is a privately held Australian bioscience company formed to develop and commercialise novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company is funded by the Australian government backed venture capital funds, AMWIN and Momentum, private investors and has won support from AusIndustry Commercial Ready Program and the NSW Government.